A 62-year-old Indian woman undergoes total gastrectomy with D2 lymphadenectomy for T2 N1 gastric adenocarcinoma. Final histopathology shows 3 out of 18 regional lymph nodes involved. There is no peritoneal involvement, and margins are negative. What is the most appropriate next step in management?

## Pathological Staging & Prognosis This patient has **T2 N1 M0 gastric cancer** (stage IIB by AJCC 8th edition). The presence of 1–2 positive regional lymph nodes (N1) indicates intermediate-risk disease requiring adjuvant therapy. ## Adjuvant Therapy Indications **Key Point:** Adjuvant chemotherapy is the standard of care for: - T2 with any N+ disease - T3/T4 regardless of N status - Patients who did not receive neoadjuvant chemotherapy **High-Yield:** The ACTS-GC trial (2018) demonstrated that adjuvant capecitabine + oxaliplatin (SOX) improves 5-year DFS from 53% to 65% in stage II–III gastric cancer. This is the most robust evidence for adjuvant chemotherapy in resected gastric cancer. ## Comparison of Adjuvant Strategies | Strategy | Indication | Evidence | Outcome | |----------|-----------|----------|----------| | Observation alone | T1 N0 only | — | Poor; 5-yr DFS ~60% for T2N1 | | Adjuvant chemotherapy | T2 N+, T3/T4 any N | ACTS-GC, GASTRIC meta-analysis | DFS improved 53% → 65%; OS improved | | Adjuvant radiotherapy alone | Rarely (R1 margin, diffuse type) | Weak evidence | Modest benefit; not standard | | Chemoradiotherapy | Locally advanced + R1 margin or high-risk features | INT-0116 (US data; less relevant in Asia) | Considered in selected cases, not routine | **Clinical Pearl:** The MAGIC trial used perioperative chemotherapy (neoadjuvant + adjuvant), but this patient did not receive neoadjuvant therapy. Adjuvant chemotherapy alone is therefore the appropriate next step to improve disease-free and overall survival. ## Decision Algorithm ```mermaid flowchart TD A[Resected gastric cancer<br/>T2 N1 M0]:::outcome --> B{Neoadjuvant chemotherapy?}:::decision B -->|Yes| C[Adjuvant chemotherapy<br/>x 3 cycles]:::action B -->|No| D[Adjuvant chemotherapy<br/>x 6 cycles]:::action C --> E[Follow-up surveillance]:::outcome D --> E F[T1 N0] --> G[Observation]:::action H[R1 margin or<br/>high-risk features] --> I[Consider chemoradiotherapy]:::action ``` **Mnemonic:** **ACTS** = **A**djuvant **C**apecitabine + oxaliplatin for **T**umors (stage II–III gastric cancer).